Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Carisbamate (Primary)
- Indications Lennox-Gastaut syndrome
- Focus Pharmacokinetics
- Sponsors SK Life Science
- 05 Dec 2019 Planned End Date changed from 1 Dec 2019 to 31 Mar 2020.
- 05 Dec 2019 Planned primary completion date changed from 1 Dec 2019 to 31 Mar 2020.
- 13 Nov 2018 New trial record